Developmental disorder associated with increased cellular nucleotidase activity.
Four unrelated patients are described with a syndrome that included developmental delay, seizures, ataxia, recurrent infections, severe language deficit, and an unusual behavioral phenotype characterized by hyperactivity, short attention span, and poor social interaction. These manifestations appeared within the first few years of life. Each patient displayed abnormalities on EEG. No unusual metabolites were found in plasma or urine, and metabolic testing was normal except for persistent hypouricosuria. Investigation of purine and pyrimidine metabolism in cultured fibroblasts derived from these patients showed normal incorporation of purine bases into nucleotides but decreased incorporation of uridine. De novo synthesis of purines and cellular phosphoribosyl pyrophosphate content also were moderately decreased. The distribution of incorporated purines and pyrimidines did not reveal a pattern suggestive of a deficient enzyme activity. Assay of individual enzymes in fibroblast lysates showed no deficiencies. However, the activity of cytosolic 5'-nucleotidase was elevated 6- to 10-fold. Based on the possibility that the observed increased catabolic activity and decreased pyrimidine salvage might be causing a deficiency of pyrimidine nucleotides, the patients were treated with oral pyrimidine nucleoside or nucleotide compounds. All patients showed remarkable improvement in speech and behavior as well as decreased seizure activity and frequency of infections. A double-blind placebo trial was undertaken to ascertain the efficacy of this supplementation regimen. Upon replacement of the supplements with placebo, all patients showed rapid regression to their pretreatment states. These observations suggest that increased nucleotide catabolism is related to the symptoms of these patients, and that the effects of this increased catabolism are reversed by administration of uridine.
Page
T
T
Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093, USA. tpage@ucsd.edu
Yu
A
A
Fontanesi
J
J
Nyhan
W L
WL
D015720:5'-Nucleotidase / Q000378:metabolism; D000243:Adenosine Deaminase / Q000378:metabolism; D000248:Adenosine Kinase / Q000378:metabolism; D001289:Attention Deficit Disorder with Hyperactivity / Q000201:enzymology* / Q000503:physiopathology; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003564:Cytidine Deaminase; D003844:DCMP Deaminase / Q000378:metabolism; D005260:Female; D005347:Fibroblasts; D006801:Humans; D008297:Male; D008780:Methyltransferases / Q000378:metabolism; D009460:Neurologic Examination; D009700:Nucleoside Deaminases / Q000378:metabolism; D009708:Nucleotidases / Q000378:metabolism*; D010430:Pentosyltransferases / Q000378:metabolism; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D013940:Thymidylate Synthase / Q000378:metabolism; D014541:Uridine Kinase / Q000378:metabolism
D011687:Purines; D011743:Pyrimidines; D008780:Methyltransferases; D013940:Thymidylate Synthase; D010430:Pentosyltransferases; C067995:nucleoside phosphorylase; D000248:Adenosine Kinase; D014541:Uridine Kinase; D009708:Nucleotidases; D015720:5'-Nucleotidase; D009700:Nucleoside Deaminases; D003844:DCMP Deaminase; D000243:Adenosine Deaminase; D003564:Cytidine Deaminase; C011530:deoxycytidine deaminase